Author: admin

DelveInsight’s “Aplastic Anemia Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Aplastic Anemia, historical and forecasted epidemiology as well as the Aplastic Anemia market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Get a Free sample for the Aplastic Anemia Market Report

https://www.delveinsight.com/sample-request/aplastic-anemia-market

Some of the key facts of the Aplastic Anemia Market Report:

• The Acromegaly market size was valued at approximately USD 1.3 billion in 2025 and is expected to experience steady growth during the forecast period from 2026 to 2036, registering a CAGR of around 1.5%.

• Regeneron announced in 2025 that they have discontinued the study of REGN7257 in Aplastic anemia.

• In February 2026, Ayrmid announced presentation of additional positive results for OMISIRGE in treating SAA at TANDEM 2026.

• In April 2025, Cellenkos announced that the US FDA had granted ODD to its novel cell therapy product, CK0801. Cellenkos was planning for a registration trial of CK0801 in H2 2025.

• In December 2025, Ayrmid Ltd. (“Ayrmid” or the “Company”), the parent organization of Gamida Cell Inc., a pioneer in cell therapy innovation, has announced that the U.S. Food and Drug Administration (“FDA”) has approved Omisirge (Omidubicel-onlv) for treating Severe Aplastic Anemia (SAA).

• In September 2025, Omidubicel is a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy sourced from cord blood. Marketed as Omisirge®, it is approved for adults and pediatric patients aged 12 and older with hematologic malignancies who are scheduled for umbilical cord blood transplantation following myeloablative conditioning, aiming to shorten neutrophil recovery time and lower the risk of infection.

• According to DelveInsight’s analysis, the Aplastic anemia market across the 7MM reached approximately USD 300 million in 2025, with the US holding the largest share.

• The overall market of Aplastic anemia in the 7MM is expected to cross USD 300 million by 2036.

• The aplastic anemia market is projected to decline from 2026 onward, driven by the anticipated entry of generic versions of PROMACTA.

• Treatment for SAA in the elderly is uncertain, considering both illness characteristics and the patient’s health to minimize treatment-related risks. Hematopoietic cell transplantation (HCT) is often a second-line choice for elderly SAA patients.

• As per DelveInsight estimates, the total incident population of aplastic anemia in the 7MM was around 2,600 cases in 2025. These cases are projected to increase during the forecast period.

• Japan accounted for the highest Incident cases of aplastic anemia in the 7MM in 2025, with approximately 850 cases.

• In the United States, it is observed that aplastic anemia occurs primarily in the age group of 60 years and above, accounting for ~56% of all cases, in 2025.

• Among EU4 and the UK, Germany accounted for the highest number of aplastic anemia cases, followed by France, whereas Spain accounted for the lowest number of cases in 2025.

• Among the severity-specific cases, SAA was more common in the United States, with ~430 cases in 2025.

• Key Aplastic Anemia Companies: Teva Pharmaceuticals, Pfizer, Regeneron Pharmaceuticals, Gamida-Cell, Kyowa Kirin, Novartis, Jiangsu HengRui Medicine Co., Ltd., Janssen Scientific Affairs, LLC, and others

• Key Aplastic Anemia Therapies: ALVAIZ (eltrombopag choline), PF-06462700, REGN7257, Omidubicel, Romiplostim, Eltrombopag, AMG531, Eltrombopag, Hetrombopag Olamine, Ibrutinib, and others

• The Aplastic Anemia epidemiology based on gender analyzed that the male-to-female ratio is approximately 1:1

• The Aplastic Anemia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Aplastic Anemia pipeline products will significantly revolutionize the Aplastic Anemia market dynamics.

Aplastic Anemia Overview

According to the National Institutes of Health, pancytopenia and decreased or nonexistent hematopoietic precursors in the bone marrow are symptoms of aplastic anaemia, which is a state of chronic primary hematopoietic failure brought on by damage.

To Know in detail about the Aplastic Anemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Aplastic Anemia Market Forecast

Aplastic Anemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Aplastic Anemia Epidemiology Segmentation:

The Aplastic Anemia market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Incident Cases of Aplastic Anemia

• Severity-specific Cases of Aplastic Anemia

• Age-specific Cases of Aplastic Anemia

Download the report to understand which factors are driving Aplastic Anemia epidemiology trends @ Aplastic Anemia Epidemiology Forecast

Aplastic Anemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Aplastic Anemia market or expected to get launched during the study period. The analysis covers Aplastic Anemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Aplastic Anemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Aplastic Anemia Therapies and Key Companies

• OMISIRGE (omidubicel-onlv): Ayrmid (Gamida Cell)

• ALVAIZ (eltrombopag choline): Teva Pharmaceuticals

• ROMIPLATE (romiplostim): Kyowa Kirin

• CK0801: Cellenkos

• ALVAIZ (eltrombopag choline): Teva Pharmaceuticals

• REGN7257: Regeneron Pharmaceuticals

• PF-06462700: Pfizer

• Omidubicel: Gamida-Cell

• Romiplostim: Kyowa Kirin

• Eltrombopag: Novartis

• AMG531: Kyowa Kirin

• Eltrombopag: Novartis

• Hetrombopag Olamine: Jiangsu HengRui Medicine Co., Ltd.

• Ibrutinib: Janssen Scientific Affairs, LLC

Discover more about therapies set to grab major Aplastic Anemia market share @ Aplastic Anemia Treatment Market

Aplastic Anemia Market Drivers

• Increasing awareness and improved diagnosis: Greater awareness among healthcare professionals and advancements in diagnostic techniques are leading to earlier and more accurate detection of aplastic anemia.

• Advancements in treatment options: The development of immunosuppressive therapies, hematopoietic stem cell transplantation, and novel targeted therapies is improving patient outcomes and driving market growth.

• Growing investment in rare disease research: Pharmaceutical companies and research organizations are increasing investments in rare hematologic disorders, supporting new drug development.

• Rising healthcare expenditure: Improved access to advanced healthcare facilities and treatment options is contributing to increased adoption of therapies.

Aplastic Anemia Market Barriers

• High cost of treatment: Advanced therapies such as stem cell transplantation and long-term immunosuppressive treatments can be expensive, limiting accessibility.

• Limited donor availability for transplantation: Successful hematopoietic stem cell transplantation often depends on compatible donors, which can restrict treatment options.

• Adverse effects associated with therapies: Immunosuppressive treatments and transplantation procedures may cause significant side effects and complications.

• Limited patient population: As a rare disease, the smaller patient pool may restrict market expansion and reduce commercial incentives for drug development.

• Regulatory and clinical trial challenges: Stringent regulatory requirements and difficulties in recruiting patients for trials can delay the approval of new therapies.

Scope of the Aplastic Anemia Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Aplastic Anemia Companies: Teva Pharmaceuticals, Pfizer, Regeneron Pharmaceuticals, Gamida-Cell, Kyowa Kirin, Novartis, Jiangsu HengRui Medicine Co., Ltd., Janssen Scientific Affairs, LLC, and others

• Key Aplastic Anemia Therapies: ALVAIZ (eltrombopag choline), PF-06462700, REGN7257, Omidubicel, Romiplostim, Eltrombopag, AMG531, Eltrombopag, Hetrombopag Olamine, Ibrutinib, and others

• Aplastic Anemia Therapeutic Assessment: Aplastic Anemia current marketed and Aplastic Anemia emerging therapies

• Aplastic Anemia Market Dynamics: Aplastic Anemia market drivers and Aplastic Anemia market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Aplastic Anemia Unmet Needs, KOL’s views, Analyst’s views, Aplastic Anemia Market Access and Reimbursement

To know more about Aplastic Anemia companies working in the treatment market, visit @ Aplastic Anemia Clinical Trials and Therapeutic Assessment

Table of Contents

1. Aplastic Anemia Market Report Introduction

2. Executive Summary for Aplastic Anemia

3. SWOT analysis of Aplastic Anemia

4. Aplastic Anemia Patient Share (%) Overview at a Glance

5. Aplastic Anemia Market Overview at a Glance

6. Aplastic Anemia Disease Background and Overview

7. Aplastic Anemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Aplastic Anemia

9. Aplastic Anemia Current Treatment and Medical Practices

10. Aplastic Anemia Unmet Needs

11. Aplastic Anemia Emerging Therapies

12. Aplastic Anemia Market Outlook

13. Country-Wise Aplastic Anemia Market Analysis (2022–2036)

14. Aplastic Anemia Market Access and Reimbursement of Therapies

15. Aplastic Anemia Market Drivers

16. Aplastic Anemia Market Barriers

17. Aplastic Anemia Appendix

18. Aplastic Anemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Aplastic Anemia Market Expected to Experience Accelerated Growth and Market Evolution by 2036 – DelveInsight | Pfizer, Regeneron Pharma, Gamida-Cell, Kyowa Kirin, Novartis, Jiangsu HengRui

DelveInsight’s “Homozygous Familial Hypercholesterolemia Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Homozygous Familial Hypercholesterolemia, historical and forecasted epidemiology as well as the Homozygous Familial Hypercholesterolemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Get a Free sample for the Homozygous Familial Hypercholesterolemia Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/homozygous-familial-hypercholesterolemia-market

Some of the key facts of the Homozygous Familial Hypercholesterolemia Market Report:

• The Homozygous Familial Hypercholesterolemia market size is anticipated to grow with a significant CAGR during the study period (2022-2036).

• In March 2026, Chiesi Global Rare Diseases announced that the US FDA approved Lomitapide (JUXTAPID) for pediatric patients with HoFH, expanding its indication to younger populations and addressing a significant unmet need in early disease management.

• In August 2025, Amgen reported that the US FDA expanded the label of Evolocumab (REPATHA) to include patients at increased cardiovascular risk and reinforced its use in genetic conditions such as HoFH, supporting broader clinical adoption.

• In September 2025, the US FDA expanded approval of Evinacumab (EVKEEZA) to include pediatric patients aged ≥1 year with HoFH, highlighting its growing role as a key LDL-C lowering therapy independent of LDL receptor function.

• In March 2025, Esperion (NASDAQ: ESPR) has announced that, following discussions with the U.S. Food and Drug Administration (FDA), it has received regulatory alignment to proceed with Phase 3 clinical trials of bempedoic acid—both as a standalone therapy and in combination with ezetimibe—in pediatric patients with heterozygous and homozygous familial hypercholesterolemia (HeFH and HoFH). The company intends to launch these trials later this year. Notably, the FDA has previously granted orphan drug designation to bempedoic acid for the treatment of HoFH.

• In January 2025, LIB Therapeutics Inc. (LIB), a privately held, late-stage biopharmaceutical company developing Lerodalcibep a next-generation PCSK9 inhibitor—announced that results from its Phase 3 LIBerate-HoFH trial have been published in The Lancet Diabetes & Endocrinology (Raal, F.J. et al., 2025). The study evaluated Lerodalcibep in a globally diverse population with homozygous familial hypercholesterolemia (HoFH).

• According to DelveInsight’s estimates, the total diagnosed prevalent cases of HoFH in the 7MM were approximately 1,840 in 2025.

• According to estimates based on DelveInsight’s epidemiology model, the total diagnosed prevalent cases of HoFH in the US were estimated to be approximately ~870 in 2025.

• Among the 7MM, the EU4 and the UK accounted for approximately 40% of the total diagnosed prevalent cases of HoFH in 2025, which is expected to increase further during the study period.

• According to DelveInsight’s analysis in the US, nearly 80% of cases were reported due to mutation in the LDLR gene.

• Assessments as per DelveInsight’s analysts showed that Germany accounted for the highest total diagnosed prevalent cases of HoFH in 2025 among EU4 and the UK.

• Key Homozygous Familial Hypercholesterolemia Companies: Arrowhead Pharmaceutical, Novartis, Alnylam Pharmaceutical, LIB Therapeutics, Amryt Pharma, Novartis, Ultragenyx Pharmaceutical, Arrowhead Pharmaceuticals, Sanofi, Cerenis Therapeutics, Aegerion Pharmaceuticals, The Medicines Company, Akeso, Aegerion Pharmaceuticals, and others

• Key Homozygous Familial Hypercholesterolemia Therapies: ARO-ANG3, LEQVIO (inclisiran/KJX839), Lerodalcibep (LIB003), Lomitapide, Inclisiran, Evinacumab, ARO-ANG 3 Injection, Alirocumab, CER-001, lomitapide, ALN-PCSSC, AK102, AEGR-733, and others

• The Homozygous Familial Hypercholesterolemia epidemiology based on mutation-specific cases analyzed that a mutation in the LDLR gene accounted for the highest diagnosed prevalent cases in the US

• The Homozygous Familial Hypercholesterolemia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Homozygous Familial Hypercholesterolemia pipeline products will significantly revolutionize the Homozygous Familial Hypercholesterolemia market dynamics.

Homozygous Familial Hypercholesterolemia Overview

Homozygous Familial Hypercholesterolemia (HoFH) is a rare and severe genetic disorder characterized by extremely high levels of low-density lipoprotein cholesterol (LDL-C) from birth. It is caused by mutations in both alleles of genes involved in the clearance of LDL-C from the bloodstream, typically the LDL receptor gene. This condition leads to early and aggressive atherosclerosis, increasing the risk of heart attacks, strokes, and other cardiovascular diseases at a young age.

To Know in detail about the Homozygous Familial Hypercholesterolemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Homozygous Familial Hypercholesterolemia Market Forecast

Homozygous Familial Hypercholesterolemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Homozygous Familial Hypercholesterolemia Epidemiology Segmentation:

The Homozygous Familial Hypercholesterolemia market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of HoFH in the 7MM

• Mutation-specific Diagnosed Prevalent Cases of HoFHin the 7MM

Download the report to understand which factors are driving Homozygous Familial Hypercholesterolemia epidemiology trends @ Homozygous Familial Hypercholesterolemia Epidemiology Forecast

Homozygous Familial Hypercholesterolemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Homozygous Familial Hypercholesterolemia market or expected to get launched during the study period. The analysis covers Homozygous Familial Hypercholesterolemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Homozygous Familial Hypercholesterolemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Homozygous Familial Hypercholesterolemia Therapies and Key Companies

• Zodasiran (ARO-ANG3): Arrowhead Pharmaceuticals

• Lerodalcibep (LIB003) (LEROCHOL): LIB Therapeutics

• ARO-ANG3: Arrowhead Pharmaceutical

• LEQVIO (inclisiran/KJX839: Novartis/ Alnylam Pharmaceutical

• Lerodalcibep (LIB003): LIB Therapeutics

• Lomitapide: Amryt Pharma

• Inclisiran: Novartis

• Evinacumab: Ultragenyx Pharmaceutical

• ARO-ANG 3 Injection: Arrowhead Pharmaceuticals

• Alirocumab: Sanofi

• CER-001: Cerenis Therapeutics

• lomitapide: Aegerion Pharmaceuticals

• ALN-PCSSC: The Medicines Company

• AK102: Akeso

• AEGR-733: Aegerion Pharmaceuticals

Discover more about therapies set to grab major Homozygous Familial Hypercholesterolemia market share @ Homozygous Familial Hypercholesterolemia Treatment Landscape

Homozygous Familial Hypercholesterolemia Market Strengths

• The clarity in disease understanding and pathogenesis has driven the development of novel pharmacological options like PCSK9 inhibitors, ANGPTL3 inhibitors, and MTP inhibitor

• Updated international diagnostic and clinical guidelines for FH and HoFH enable evidence-based therapeutic approaches and screening strategies for early identification

• Advances in research have led to the discovery of novel molecules like siRNA and recombinant fusion protein that may offer novel options to lower LDL significantly

Homozygous Familial Hypercholesterolemia Market Opportunities

• Preclinical studies have yielded gene therapy and CRISPR-based gene editing approaches; conducting further research and clinical trials may offer curative therapy.

• Current therapies do not impart sufficient cholesterol-lowering allowing pharma players to bring newer, more potent, and better LDL-C lowering therapies and prevent ASCVD in HoFH patients.

• Advancements in healthcare technologies and digital health solutions can potentially enhance early detection and personalized management of HoFH.

Scope of the Homozygous Familial Hypercholesterolemia Market Report

• Study Period: 2022-2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Homozygous Familial Hypercholesterolemia Companies: Arrowhead Pharmaceutical, Novartis, Alnylam Pharmaceutical, LIB Therapeutics, Amryt Pharma, Novartis, Ultragenyx Pharmaceutical, Arrowhead Pharmaceuticals, Sanofi, Cerenis Therapeutics, Aegerion Pharmaceuticals, The Medicines Company, Akeso, Aegerion Pharmaceuticals, and others

• Key Homozygous Familial Hypercholesterolemia Therapies: ARO-ANG3, LEQVIO (inclisiran/KJX839), Lerodalcibep (LIB003), Lomitapide, Inclisiran, Evinacumab, ARO-ANG 3 Injection, Alirocumab, CER-001, lomitapide, ALN-PCSSC, AK102, AEGR-733, and others

• Homozygous Familial Hypercholesterolemia Therapeutic Assessment: Homozygous Familial Hypercholesterolemia current marketed and Homozygous Familial Hypercholesterolemia emerging therapies

• Homozygous Familial Hypercholesterolemia Market Dynamics: Homozygous Familial Hypercholesterolemia market drivers and Homozygous Familial Hypercholesterolemia market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Homozygous Familial Hypercholesterolemia Unmet Needs, KOL’s views, Analyst’s views, Homozygous Familial Hypercholesterolemia Market Access and Reimbursement

To know more about Homozygous Familial Hypercholesterolemia companies working in the treatment market, visit @ Homozygous Familial Hypercholesterolemia Clinical Trials and Treatments

Table of Contents

1. Homozygous Familial Hypercholesterolemia Market Report Introduction

2. Executive Summary for Homozygous Familial Hypercholesterolemia

3. SWOT analysis of Homozygous Familial Hypercholesterolemia

4. Homozygous Familial Hypercholesterolemia Patient Share (%) Overview at a Glance

5. Homozygous Familial Hypercholesterolemia Market Overview at a Glance

6. Homozygous Familial Hypercholesterolemia Disease Background and Overview

7. Homozygous Familial Hypercholesterolemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Homozygous Familial Hypercholesterolemia

9. Homozygous Familial Hypercholesterolemia Current Treatment and Medical Practices

10. Homozygous Familial Hypercholesterolemia Unmet Needs

11. Homozygous Familial Hypercholesterolemia Emerging Therapies

12. Homozygous Familial Hypercholesterolemia Market Outlook

13. Country-Wise Homozygous Familial Hypercholesterolemia Market Analysis (2022–2036)

14. Homozygous Familial Hypercholesterolemia Market Access and Reimbursement of Therapies

15. Homozygous Familial Hypercholesterolemia Market Drivers

16. Homozygous Familial Hypercholesterolemia Market Barriers

17. Homozygous Familial Hypercholesterolemia Appendix

18. Homozygous Familial Hypercholesterolemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Homozygous Familial Hypercholesterolemia Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 – DelveInsight | Arrowhead Pharma, Novartis, Alnylam Pharma, LIB Therapeutics

DelveInsight’s “Common Warts Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Common Warts, historical and forecasted epidemiology as well as the Common Warts market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Get a Free sample for the Common Warts Market Report:

https://www.delveinsight.com/report-store/common-warts-market

Some of the key facts of the Common Warts Market Report:

• The Common Warts market size was valued at approximately USD 1.0 billion in 2025 and is anticipated to witness substantial growth during the forecast period from 2026 to 2036, driven by increasing disease prevalence, growing treatment awareness, and advancements in dermatological therapies.

• In January 2026, Verrica Pharmaceuticals Inc. recently announced the launch of a global Phase III clinical development program to evaluate VP-102 for the treatment of common warts, with the first patient dosed in December 2025. This milestone marks an expansion of VP-102’s clinical development beyond its approved use in molluscum contagiosum and underscores the company’s continued commitment to addressing unmet needs in dermatology.

• In July 2025, Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a dermatology-focused therapeutics company specializing in treatments for skin conditions requiring medical intervention, announced it has signed a second amendment to its Collaboration and Licensing Agreement with Torii Pharmaceutical Co. Ltd. (“Torii”). This amendment supports the launch of a global pivotal Phase 3 clinical trial for Verrica’s product, YCANTH®, aimed at treating common warts.

• In February 2025, Nielsen BioSciences, Inc., a privately held biopharmaceutical company based in San Diego, announced the successful enrollment of the final participant in CFW-3A—a Phase 3, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of CANDIN® (Candida albicans Skin Test Antigen for Cellular Hypersensitivity) for treating common warts (Verruca vulgaris) in both adolescents and adults. CANDIN is not yet approved for this indication.

• According to DelveInsight’s estimates, in 2025, the total number of prevalent cases of common warts in the 7MM were ~15,063,000.

• The highest burden is observed in children and adolescents, while immunocompromised individuals also show significantly increased incidence and persistence rates.

• HPV infections causing cutaneous warts are most commonly linked to low-risk types 1, 2, 4, 27, and 57, which account for the majority of common wart cases.

• In Europe, warts were identified as the most common skin disease, with a prevalence of 41.3%, highlighting their significant burden on dermatological health in the region.

• Plantar warts account for a significant proportion of cases in clinical settings, as they are more likely to become symptomatic due to pressure and pain on weight-bearing surfaces.

• Despite being benign, common warts show a high spontaneous resolution rate (within 1–2 years in many cases), but a substantial proportion persist or recur due to immune evasion by HPV.

• As per the secondary analysis, warts are a common condition worldwide, affecting about 10% of the population, with prevalence rising to 10–20% in school-aged children; they are rare in infancy and early childhood, increase during school years, peak between 12 and 16 years, and are more frequently observed in immunosuppressed individuals and meat handlers.

• Key Common Warts Companies: Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma/ Iwaki Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma Inc., ViroXis Corporation, Maruho Co., Ltd., Veradermics, Inc., Graceway Pharmaceuticals, LLC, MEDA Pharma, LEO Pharma, and others

• Key Common Warts Therapies: CANDIN, VP-102, FIT039, A-101, KNP2002, 10% EISO, CLS006, VDMN-21, Resiquimod, Imiquimod, Picato, and others

• The Common Warts epidemiology based on gender analyzed that the diagnosed prevalent cases were observed to be same for male and female in the 7MM

• The Common Warts market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Common Warts pipeline products will significantly revolutionize the Common Warts market dynamics.

Common Warts Overview

Common warts are benign growths on the skin caused by an infection with human papillomavirus (HPV). They are typically rough, raised, and have a grainy appearance. Common warts are most frequently found on the hands, fingers, and around the nails, but they can appear on other areas of the body as well.

To Know in detail about the Common Warts market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Common Warts Market Forecast

Common Warts Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Common Warts Epidemiology Segmentation:

The Common Warts market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Prevalent Cases of Warts

• Total Diagnosed Prevalent Cases of Warts

• Total Diagnosed Prevalent Cases of Common Warts

• Treated Cases of Common Warts

Download the report to understand which factors are driving Common Warts epidemiology trends @ Common Warts Epidemiology Forecast

Common Warts Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Common Warts market or expected to get launched during the study period. The analysis covers Common Warts market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Common Warts Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Common Warts Therapies and Key Companies

• CANDIN: Nielsen BioSciences/Maruho

• VP-102: Verrica Pharmaceutical

• FIT039: Kino Pharma/ Iwaki Pharmaceutical

• A-101: Aclaris Therapeutics, Inc.

• KNP2002: KinoPharma Inc.

• 10% EISO: ViroXis Corporation

• CLS006: Maruho Co., Ltd.

• VDMN-21: Veradermics, Inc.

• Resiquimod: Graceway Pharmaceuticals, LLC

• Imiquimod: MEDA Pharma

• Picato: LEO Pharma

Discover more about therapies set to grab major Common Warts market share @ Common Warts Treatment Market

Common Warts Market Drivers

• High Prevalence of Human Papillomavirus (HPV) Infections: Common warts are caused by HPV, and the widespread prevalence of the virus continues to drive demand for effective treatment options.

• Growing Awareness of Skin Health: Increased awareness regarding dermatological conditions and the availability of treatment options is encouraging more patients to seek medical care.

• Advancements in Wart Treatment Technologies: The development of novel topical therapies, immunotherapies, laser treatments, and cryotherapy devices is improving treatment outcomes.

• Rising Demand for Minimally Invasive Procedures: Patients are increasingly opting for non-surgical and minimally invasive wart removal techniques due to their convenience and effectiveness.

Common Warts Market Barriers

• High Rate of Spontaneous Resolution: Many common warts resolve naturally without treatment, which can reduce the demand for medical intervention.

• Recurrence After Treatment: Warts may reappear even after successful treatment, posing challenges for long-term disease management.

• Availability of Over-the-Counter (OTC) Products: Widely available OTC treatments may limit the uptake of prescription therapies and clinical procedures.

• Limited Awareness in Certain Regions: Lack of awareness regarding available treatment options can result in delayed care-seeking behavior.

Scope of the Common Warts Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Common Warts Companies: Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma/ Iwaki Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma Inc., ViroXis Corporation, Maruho Co., Ltd., Veradermics, Inc., Graceway Pharmaceuticals, LLC, MEDA Pharma, LEO Pharma, and others

• Key Common Warts Therapies: CANDIN, VP-102, FIT039, A-101, KNP2002, 10% EISO, CLS006, VDMN-21, Resiquimod, Imiquimod, Picato, and others

• Common Warts Therapeutic Assessment: Common Warts current marketed and Common Warts emerging therapies

• Common Warts Market Dynamics: Common Warts market drivers and Common Warts market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Common Warts Unmet Needs, KOL’s views, Analyst’s views, Common Warts Market Access and Reimbursement

To know more about Common Warts companies working in the treatment market, visit @ Common Warts Clinical Trials and Therapeutic Assessment

Table of Contents

1. Common Warts Market Report Introduction

2. Executive Summary for Common Warts

3. SWOT analysis of Common Warts

4. Common Warts Patient Share (%) Overview at a Glance

5. Common Warts Market Overview at a Glance

6. Common Warts Disease Background and Overview

7. Common Warts Epidemiology and Patient Population

8. Country-Specific Patient Population of Common Warts

9. Common Warts Current Treatment and Medical Practices

10. Common Warts Unmet Needs

11. Common Warts Emerging Therapies

12. Common Warts Market Outlook

13. Country-Wise Common Warts Market Analysis (2022–2036)

14. Common Warts Market Access and Reimbursement of Therapies

15. Common Warts Market Drivers

16. Common Warts Market Barriers

17. Common Warts Appendix

18. Common Warts Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Common Warts Market Forecast Signals Robust Industry Growth Through 2036 – DelveInsight | Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics

DelveInsight’s report, “Osteoarthritis Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Osteoarthritis landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Osteoarthritis market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

Get a Free sample for the Osteoarthritis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/osteoarthritis-market

Some of the key facts of the Osteoarthritis Market Report:

• The Osteoarthritis market size was valued at approximately USD 32.5 billion in 2025 and is projected to reach nearly USD 47.0 billion by 2036, expanding at a CAGR of 3% during the forecast period from 2026 to 2036.

• In 2023, opioids accounted for the largest share of the Osteoarthritis treatment market by therapy class in the United States, generating approximately USD 9,200 million.

• In February 2026, OrthoTrophix Inc., a privately held company focused on developing innovative investigational treatments for Osteoarthritis, has announced the ahead-of-schedule completion of patient enrollment in its Phase 2b clinical trial. The study is assessing intra-articular TPX-100 for Knee osteoarthritis. This multicenter trial in the United States began in May 2025 and is anticipated to conclude in the first quarter of 2027.

• In January 2026, 4Moving Biotech (4MB), a clinical-stage biotechnology company focused on developing next-generation, disease-modifying therapies for osteoarthritis (OA), announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for 4P004. This clearance allows the Phase 2a INFLAM MOTION clinical trial to expand into the United States. The FDA approval represents a strategic milestone in 4MB’s global clinical efforts across Europe, Canada, and now the U.S., strengthening the company’s position as a leader in the pursuit of the first disease-modifying osteoarthritis drug (DMOAD) for patients worldwide.

• In November 2025, Novo Nordisk has released new findings from the OASIS 4 Phase 3 trial, which investigated various patient populations and hypotheses, further supporting the potential of this therapy. Injectable semaglutide 2.4 mg, marketed as Wegovy®, is approved in the EU as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with a BMI of ≥30 kg/m² (obesity) or ≥27 kg/m² (overweight) with at least one weight-related comorbidity. Wegovy® is also approved for pediatric patients aged 12 and older with an initial BMI at or above the 95th percentile and body weight over 60 kg. The label highlights clinical evidence of major adverse cardiovascular event (MACE) risk reduction, improvements in HFpEF-related symptoms and physical function, and pain relief for knee osteoarthritis.

• In May 2025, Lipogems announced the successful completion of its ARISE I U.S. FDA IDE Study, with the final patient visit now concluded. This marks a significant milestone in progressing Lipogems as a treatment option for knee osteoarthritis (OA) in patients who are not eligible for or ready to undergo knee replacement. The double-blind, randomized controlled trial included 173 participants across 18 leading U.S. clinical sites. The study’s primary focus is on assessing pain relief and functional improvement 12 months after injection. Results on efficacy and safety are anticipated by late 2025.

• In May 2025, Genascence Corporation, a clinical-stage biotech firm focused on transforming musculoskeletal disease treatment through gene therapy, reported positive 12-month safety and biomarker findings from its Phase 1b DONATELLO trial of GNSC-001. This investigational gene therapy targets interleukin 1 (IL-1) for treating knee osteoarthritis (OA). The 12-month results confirmed the trial met its primary endpoint, showing consistent safety and tolerability across all tested doses. Additionally, the study met a key secondary endpoint, demonstrating sustained IL-1Ra expression in synovial fluid, reinforcing the six-month data previously reported.

• In May 2025, Moximed, a pioneering medical device company focused on enhancing care for individuals with knee osteoarthritis (OA), announced that the first patients have been treated in its latest randomized controlled trial (RCT). The MOTION study is a prospective, multicenter trial designed to compare the effectiveness of the MISHA Knee System against non-surgical treatment options in patients with medial knee osteoarthritis.

• In April 2025, Pacira BioSciences reported that its gene therapy candidate, PCRX-201 (enekinragene inzadenovec), showed long-lasting improvements in knee pain, mobility, and stiffness for up to two years in a Phase I trial. Participants received a single local injection of the therapy. The study included 72 individuals aged 30 to 80, categorized based on the severity of their knee osteoarthritis using the Kellgren-Lawrence (K/L) grading system.

• In April 2025, Israel-based Enlivex Therapeutics announced the completion of enrollment for the Phase II portion of its Phase I/II trial evaluating Allocetra, an off-the-shelf cell therapy for moderate to severe knee osteoarthritis. In this phase, over 133 subjects were randomized and treated. The multi-center, randomized trial is divided into two stages, with Phase I being an open-label, dose-escalation study focused on assessing the safety and tolerability of Allocetra injections into the knee.

• In March 2025, RION, a clinical-stage company specializing in regenerative medicine and exosome-based therapies, announced the enrollment of the first patient in its Phase 1b trial of Purified Exosome Product™ (PEP™) for treating Osteoarthritis (OA). This marks a significant step in RION’s mission to develop cutting-edge regenerative solutions for unmet medical needs.

• In 2025, Opioids captured the highest market size of osteoarthritis by therapies, i.e., around USD 9,500 million in the US.

• Amongst EU4 and the UK, Germany will capture the maximum revenue share, followed by Spain and France in 2036.

• The upcoming therapies for osteoarthritis are expected to combat the current unmet needs faced by patients with osteoarthritis.

• As per the study by Nalamachu et al. (2020), 41%, 37%, and 22% of the patients with knee osteoarthritis were reported for mild, moderate, and severe pain, respectively, in the US.

• In a study by Schild et al. (2021), patient-level data was extracted from the German Institut für Angewandte Gesundheitsforschung (InGef) database. Of 4,932,543 individuals sampled, 238,306 patients with osteoarthritis were included in the analysis: 80,055 (34%) categorised as having chronic pain (24,463 via opioid prescription) and 158,251 (66%) categorised as not having chronic pain.

• Osteoarthritis is one of the most common chronic diseases in the elderly population, contributing approximately 90–95% of all osteoarthritis cases (people above 40), and its prevalence increases with age.

• It is estimated that the number of cases of osteoarthritis will rise in the coming years because of the rising aging population and obesity, affecting the total pool of knee osteoarthritis.

• In 2025, the total number of diagnosed cases of osteoarthritis was around 99,000 cases in the 7MM, which is anticipated to increase during the forecast period [2026–2036].

• According to Iolascon et al. (2024), in Italy, the knee osteoarthritis burden significantly affects the national healthcare system and society. Knee osteoarthritis accounts for over 5 million prevalent cases and an age-standardized prevalence rate of 4066 cases per 100,000.

• In Japan, the total diagnosed cases of knee osteoarthritis reached 11,500,000 in 2025.

• Key Osteoarthritis Companies: Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharmaceuticals Inc., OliPass Corporation, Bone Therapeutics, Techfields Pharma, Biosplice Therapeutics, and others

• Key Osteoarthritis Therapies: M6495, PPV 06, LG00034053, StroMel, TTAX03, EP-104IAR, OLP 1002, JTA-004, X 0002, Lorecivivint, and others

• The Osteoarthritis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteoarthritis pipeline products will significantly revolutionize the Osteoarthritis market dynamics.

Osteoarthritis Overview

Osteoarthritis is the most common form of arthritis, characterized by the gradual breakdown of cartilage the protective tissue at the ends of bones. As the cartilage wears down, bones begin to rub against each other, leading to pain, stiffness, swelling, and reduced joint mobility.

It most commonly affects weight-bearing joints such as the knees, hips, and spine, as well as the hands. Osteoarthritis is strongly associated with aging, but other risk factors include obesity, joint injuries, genetics, and repetitive stress on joints.

To Know in detail about the Osteoarthritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Osteoarthritis Market Forecast

Osteoarthritis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Osteoarthritis Epidemiology Segmentation:

The Osteoarthritis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Diagnosed Prevalence Cases of Osteoarthritis

• Joint site-specific Prevalence of Osteoarthritis

• Gender-specific Prevalence of Osteoarthritis

• Age-specific Prevalence of Osteoarthritis

• Severity-specific Prevalence of Osteoarthritis

Download the report to understand which factors are driving Osteoarthritis epidemiology trends @ Osteoarthritis Epidemiology Forecast

Osteoarthritis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Osteoarthritis market or expected to get launched during the study period. The analysis covers Osteoarthritis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Osteoarthritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Osteoarthritis Therapies and Key Companies

• JOYCLU: Ono Pharmaceutical/Seikagaku

• TRILURON: Fidia Farmaceutici

• Pentosan polysulfate sodium (ZILOSUL): Paradigm Biopharma

• LEVI-04: Levicept

• ELIXCYTE: UnicoCell Biomed

• Retatrutide (LY3437943): Eli Lilly Company

• ZILRETTA: Flexion Therapeutics/Pacira BioSciences

• CINGAL: Anika Therapeutics

• TRIVISC: OrthogenRx / Avanos Medical

• VISCO-3: Zimmer Biomet/Seikagaku Corporation

• LNA043: Novartis

• ReNu (Amniotic Suspension Allograft): Organogenesis

• CNTX-4975: Centrexion Therapeutics

• JTA-004: BioSenic (Bone Therapeutics)

• M6495: Merck KGaA

• PPV 06: Peptinov

• LG00034053: LG Chem

• StroMel: Akan Bioscience

• TTAX03: BioTissue,Inc.

• EP-104IAR: Eupraxia Pharmaceuticals Inc.

• OLP 1002: OliPass Corporation

• JTA-004: Bone Therapeutics

• X 0002: Techfields Pharma

• Lorecivivint: Biosplice Therapeutics

Discover more about therapies set to grab major Osteoarthritis market share @ Osteoarthritis Treatment Landscape

Osteoarthritis Market Drivers

• Rising global prevalence driven by aging populations and increasing life expectancy

• Growing incidence of obesity and sedentary lifestyles, key risk factors for osteoarthritis

• Increasing awareness and early diagnosis of joint disorders

• Advancements in pain management therapies, including NSAIDs, biologics, and regenerative approaches

• Expanding pipeline of disease-modifying osteoarthritis drugs (DMOADs)

• Technological progress in joint replacement surgeries and minimally invasive procedures

• Increased healthcare spending and improved access to orthopedic care

• Growing adoption of combination therapies (pharmacological + physical therapy)

Osteoarthritis Market Barriers

• Lack of curative or disease-modifying treatments, with most therapies focused on symptom relief

• High cost associated with advanced treatments and joint replacement surgeries

• Side effects linked to long-term use of NSAIDs and pain medications

• Stringent regulatory requirements for approval of novel therapies (especially DMOADs)

• Heterogeneous disease progression, making clinical trial design complex

• Limited awareness and delayed diagnosis in low- and middle-income regions

• Reimbursement challenges for newer and high-cost interventions

• Patient reluctance toward surgical procedures due to risks and recovery time

Scope of the Osteoarthritis Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Osteoarthritis Companies: Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharmaceuticals Inc., OliPass Corporation, Bone Therapeutics, Techfields Pharma, Biosplice Therapeutics, and others

• Key Osteoarthritis Therapies: M6495, PPV 06, LG00034053, StroMel, TTAX03, EP-104IAR, OLP 1002, JTA-004, X 0002, Lorecivivint, and others

• Osteoarthritis Therapeutic Assessment: Osteoarthritis current marketed and Osteoarthritis emerging therapies

• Osteoarthritis Market Dynamics: Osteoarthritis market drivers and Osteoarthritis market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Osteoarthritis Unmet Needs, KOL’s views, Analyst’s views, Osteoarthritis Market Access and Reimbursement

To know more about Osteoarthritis companies working in the treatment market, visit @ Osteoarthritis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Osteoarthritis Market Report Introduction

2. Executive Summary for Osteoarthritis

3. SWOT analysis of Osteoarthritis

4. Osteoarthritis Patient Share (%) Overview at a Glance

5. Osteoarthritis Market Overview at a Glance

6. Osteoarthritis Disease Background and Overview

7. Osteoarthritis Epidemiology and Patient Population

8. Country-Specific Patient Population of Osteoarthritis

9. Osteoarthritis Current Treatment and Medical Practices

10. Osteoarthritis Unmet Needs

11. Osteoarthritis Emerging Therapies

12. Osteoarthritis Market Outlook

13. Country-Wise Osteoarthritis Market Analysis (2020–2034)

14. Osteoarthritis Market Access and Reimbursement of Therapies

15. Osteoarthritis Market Drivers

16. Osteoarthritis Market Barriers

17. Osteoarthritis Appendix

18. Osteoarthritis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Osteoarthritis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2036 – DelveInsight | Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharma